By Daniella Parra
ReAlta Life Sciences said Pegtarazimod is being evaluated in a Phase 2 trial across 13 U.S. NICUs for newborns with moderate to severe neuroinflammation in HIE.
The company said that newborn rats treated with pegtarazimod after oxygen deprivation experienced greater brain cell survival and reduced inflammation, with effects comparable to standard therapeutic hypothermia.
“These new data further support pegtarazimod’s potential to address neuroinflammation in the brain by reducing detrimental microglial-mediated inflammation,” said Kenji M. Cunnion, Chief Medical Officer at ReAlta. “The mechanistic validation of pegtarazimod translating from preclinical models to the clinical biomarker findings in our STAR trial reinforces our confidence in our dual-targeting peptide platform’s ability to interrupt this damaging inflammatory cascade.”
READ MORE HEALTHCAREEDGE
Lisata Therapeutics Reports Trial Results for Pancreatic Cancer Treatment
Never Miss our Weekly Highlights HERE
